Abby Hardy, Author at BioTuesdays

Developments

Athersys opens first clinical site for Phase 2/3 COVID-19-induced ARDS trial

Athersys (NASDAQ:ATHX) and University Hospitals Cleveland Medical Center have opened the first clinical site for a Phase 2/3 study evaluating MultiStem cell therapy for COVID-19-induced acute respiratory distress...

May 1, 2020

Developments

Akari’s nomacopan meets primary and secondary endpoints in Phase 2 bullous pemphigoid trial

Akari Therapeutics’ (NASDAQ:AKTX) nomacopan met its primary safety and secondary efficacy endpoints in a Phase 2 trial of patients with bullous pemphigoid (BP). BP is a severe orphan inflammatory skin disease...

May 1, 2020

Developments

Dova Pharma subsidiary gets approval for thrombocytopenia drug in China

Dova Pharmaceuticals’ (NASDAQ:DOVA) wholly-owned subsidiary, AkaRx, reported that the China National Medical Products Administration (NMPA) approved DOPTELET for the treatment of thrombocytopenia in adult patients with...

April 30, 2020

Developments

Soligenix reports positive second cycle results from Phase 3 cutaneous T-cell lymphoma trial

Soligenix (NASDAQ:SNGX) reported positive second cycle results for its Phase 3 trial assessing SGX301 for the treatment of cutaneous T-cell lymphoma (CTCL). The study enrolled 169 patients who were randomized to receive...

April 30, 2020

Developments

Eiger doses first COVID-19 patients with peginterferon lambda

Eiger BioPharmaceuticals (NASDAQ:EIGR) dosed the first patients in its Phase 2 study of peginterferon lambda for the treatment of mild COVID-19. The study will enroll some 120 patients who will receive either a single...

April 30, 2020

Developments

Capricor reports all six COVID-19 patients treated with CAP-1002 have survived

Capricor Therapeutics (NASDAQ:CAPR) reported that all six critical COVID-19 patients who were treated with CAP-1002, an allogeneic cardiac cell therapy, have survived. The six COVID-19 patients, who were admitted to...

April 29, 2020

Developments

ERYTECH eryaspase gets FDA fast track designation for second-line pancreatic cancer

ERYTECH Pharma’s (NASDAQ:ERYP) eryaspase received FDA fast track designation for the second-line treatment of patients with metastatic pancreatic cancer. Eryaspase is being evaluated in a Phase 3 trial, called TRYbeCA...

April 29, 2020

Developments

BioXcel initiates Phase 2 hormone-refractory prostate cancer trial

BioXcel Therapeutics (NASDAQ:BTAI) initiated the Phase 2 efficacy portion of its Phase 1b/2 trial of BXCL701, in combination with pembrolizumab, an immunotherapy, for treatment emergent neuroendocrine prostate cancer...

April 28, 2020

Executive Moves

AMAG Pharma appoints Scott Myers as president and CEO

AMAG Pharmaceuticals (NASDAQ:AMAG) appointed Scott Myers as its president and CEO, and a member of the board, effective immediately. Mr. Myers was most recently chairman and CEO of Rainier Therapeutics. He replaces...

April 28, 2020

Executive Moves

PharmaJet appoints Chris Cappello as president and CEO

Chris Cappello Closely-held PharmaJet appointed Chris Cappello as its president and CEO, replacing Ron Lowy, who was appointed as executive chairman. “In the 10 years that [Mr.Cappello] has worked for PharmaJet, he has...

April 28, 2020

Author - Abby Hardy

Athersys opens first clinical site for Phase 2/3 COVID-19-induced ARDS trial

Akari’s nomacopan meets primary and secondary endpoints in Phase 2 bullous pemphigoid trial

Dova Pharma subsidiary gets approval for thrombocytopenia drug in China

Soligenix reports positive second cycle results from Phase 3 cutaneous T-cell lymphoma trial

Eiger doses first COVID-19 patients with peginterferon lambda

Capricor reports all six COVID-19 patients treated with CAP-1002 have survived

ERYTECH eryaspase gets FDA fast track designation for second-line pancreatic cancer

BioXcel initiates Phase 2 hormone-refractory prostate cancer trial

AMAG Pharma appoints Scott Myers as president and CEO

PharmaJet appoints Chris Cappello as president and CEO

Subscribe